ABSTRACT. L-Asparaginase, an effective agent in the treatment of acute lymphoblastic leukemia, may induce a diabetic state. The pathogenesis of the diabetogenic effect was studied in cultured pancreatic islets. Mean serum concentrations in three children with acute lymphoblastic leukemia were 2.4 U/mL (range 1.4-4.5) before and 31.5 U/mL (range 18.6-51.8) immediately after an intravenous injection of 1000 U/kg L-asparaginase. Glucose-induced insulin release from pancreatic islets of rat and man was measured after 3 and 7 days of culture in media with or without clinically relevant concentrations of Escherichia coli L-asparaginase (0.01-100 U/mL). After culture, the remaining insulin, glucagon, and DNA in the islets were determined. After 7 days of culture of adult rat or human islets, both the accumulation of insulin in the medium and the content of insulin and glucagon in the islets were significantly reduced in the presence of 100 U/mL Lasparaginase compared with controls. Addition of M hydrocortisone to the culture medium enhanced this effect. In newborn rat islets a significant reduction in insulin release and content was observed already in the presence of 0.1 U/mL asparaginase, whereas the glucagon content was unchanged. Removal of the drug resulted in partial recovery of the insulin secretion. To elucidate the mechanisms of action of the drug, insulin biosynthesis was studied in islets cultured in asparagine-free medium with or without asparaginase. No difference in biosynthesis was seen between media with or without asparagine, whereas 0.1 U/ mL asparaginase caused about a 50% reduction under both conditions. These results indicate that the pancreatic Pcells are particularly sensitive to L-asparaginase, suggesting that the diabetogenic effect of the drug is exerted by a direct interaction with the pancreatic P-cell and is not due to lack of exogenous supply of asparagine. (Pediatr Res 26: 158-161,1989) L-Asparaginase is an established drug for the induction or consolidation of remission in children with acute lymphoblastic leukemia. A major side effect of L-asparaginase treatment is nonketotic hyperglycemia and glycosuria, which have been reported in 10% of children receiving 10000 IU/m2 two to four times in the induction treatment in conjunction with prednisone (1). The mechanism of the hyperglycemia is not known, but a rational approach to the treatment of this adverse effect of Lasparaginase requires clarification of the pathogenesis. Decrease in insulin synthesis (2, 3), reduction in insulin release (4), and reduction of the number of insulin receptors (5) proposed. In previous in vitro studies only acute effects were measured, and extremely high doses of the drug were used (6). The aim of our study was, therefore, to elucidate the direct longterm effect of clinically relevant concentrations of L-asparaginase on the insulin release and biosynthesis in isolated rat and human pancreatic islets in culture.
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MATERIALS AND METHODS
Asparaginase activity in treated children. In three children with acute lymphoblastic leukemia, blood samples were drawn before and immediately after injection of Escherichia coli-L-asparaginase-2 (EC 3.5.1.1) (Crasnitin, Bayer, Leverkusen, West Germany) 1000 IU/kg body wt/day intravenously for 10 days to consolidate the remission, which had been induced by vincristin 2 mg/m2 weekly and prednisone 60 mg/m2 daily in 5 wk. Sera were stored at -20°C until analyzed before 1 mo in the same assay. L-Asparaginase activity in serum is stable for at least 3 mo under these conditions.
Asparaginase assay. The asparagine assay was performed according to the method described (7) . A total of 40 pL of 6.13 mM asparagine containing 7.1 pCi/mL L-[14C] asparagine (120 mCi/mmol) The Radiochemical Centre, Amersham, England) were incubated for 10 min with 10 pL serum. The reaction was stopped and protein precipitated with 75 pL ice cold 99% (w/w) ethanol. Asparagine and aspartic acid were separated by thinlayer chromatography on resin-coated plates in ethylacetate in water (8:92) . The fraction of asparagine converted to aspartic acid was then determined by liquid scintillation counting of the eluted spots. The conversion fraction asparaginelasparagine + aspartic acid indicated the asparaginase activity in the sample when compared to known controls. One unit is defined as the amount of enzyme which converts 1 pmol L-asparaginelmin.
Islet isolation and culture. Pancreatic islets were isolated from 3-to 5-d-old (newborn) and 30-d-old (adult) rats by the collagenase method as described (8) . Briefly, pancreas was treated by 1 mg/mL collagenase from Clostridium histolyticum (Boehringer Mannheim, West Germany) in Hanks' balanced salt solution (Flow Laboratories, Irvine, Scotland) supplemented with 100 000 U/L penicillin, 100 mg/L streptomycin, and 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid for 15 min at 37"C, washed in cold HBSS, and purified on a Percoll (Pharmacia, Uppsala, Sweden) gradient followed by hand-picking under a dissecting microscope.
Human islets were isolated from the pancreas of necro-kidney donors as described (9) . Pancreases from kidney donors were transported to the laboratory and treated with collagenase within 1 h after removal. Pieces of the pancreas were treated repeatedly with 1-2 mg/ml collagenase. After each 10-to 20-min period the supernatants were removed and washed in cold Hanks' balanced salt solution. Islets were hand-picked under the microscope. The isolated islets were maintained in culture medium RPMI 1640 supplemented with 10% newborn calf serum for 1-2 d before the experiments. About 50 islets were placed in Petri dishes with RPMI 1640 containing 8.5 mmol/L glucose and 0.5% normal human serum. Crasnitin was added in the proper dilution and the islets were incubated in a humidified atmosphere at 37°C. In some experiments the medium was prepared from the individual constituents with omission of Lasparagine (RPMI 1640 Select-amine-kit, Gibco, Paisley, Scotland). Medium was changed every 3 or 4 d and stored for insulin determination. No degradation of insulin took place under these culture conditions. After the culture period the islets were collected and sonicated. The homogenates were assayed for insulin, glucagon and DNA.
Insulin biosynthesis. Islets were incubated for 3 h in HBSS containing 1 mg/mL human serum albumin and 500 pCi/mL 4,5-[3H]-leucine (1 30 mCi/mM, The Radiochemical Centre) The islets were washed in Hanks' balanced salt solution containing 10 mM leucine, homogenized by sonication, and immunoprecipitated with guinea pig antiinsulin serum overnight followed by 30-min incubation with protein-A-Sepharose (Pharmacia) as described (10) . The precipitate was washed, dissolved in acetic acid, transferred to a scintillation vial with Aquasol-2 (New England Nuclear, Boston, MA), and counted in a scintillation counter.
Analytical methods. Insulin was determined by RIA, using crystalline rat insulin (Novo Research Laboratory, Bagsvaerd, Denmark) as standard in rat islet experiments and highly purified porcine insulin (Nordisk Gentoffe A/S, Gentoffe Denmark) as standard in human islet experiments. Glucagon was determined by a RIA kit (Novo). DNA was determined by a fluorometric assay (1 1). Wilcoxon's test was used for the statistical evaluation.
RESULTS
The mean activity of asparaginase in serum during leukemia treatment was 2.6 U/mL (range 1.4-4.5) before and 31.5 U/mL (range 18.6-5 1.8) immediately after an intravenous injection of L-asparaginase. None of the these patients had hyperglycemia or glucosuria during induction of remission or consolidation.
The dose dependency of asparaginase was evaluated in islets from newborn rats ( Table 1) . A significant reduction in insulin release and content was seen already at 0.1 U/mL. The glucagon and DNA content of the islets were not affected by this dose, although 1 U/mL or higher doses resulted in disintegration of the islets (data not shown).
To study the reversibility of the asparaginase effect, newborn rat islets were exposed to 0.1 U/mL for 7 d, after which asparaginase was removed and the islets cultured for another 7 d (Fig.  I) . Insulin release was significantly higher 7 d after removal of the drug than from islets exposed continuously to asparaginase ( p < 0.05). The insulin content was not significantly elevated ( Table 2) .
The combined effect of L-asparaginase, 100 U/mL, and hydrocortisone mol/L, was studied on adult rat islets (Fig. 2) . Asparaginase almost abolished the insulin release, whereas hydrocortisone had a significant effect only on d 7. A similar difference was found on the content of both insulin and glucagon in the islets after culture ( Table 3 ). The combination of the two drugs resulted in an even more marked effect than either compound alone. No significant change in DNA content was seen.
The effect of 100 U/mL of L-asparaginase was studied in islets isolated from three human kidney donors. Both insulin release and content were markedly depressed by exposure to L-asparaginase, whereas DNA content was unchanged (Table 4) .
To elucidate the mechanism behind the effect of L-asparaginase, insulin biosynthesis was studied in rat islets cultured in media with or without asparagine. No difference was seen in control islets, whether or not asparagine was present (Table 5 ), whereas 0.1 U/mL L-asparaginase resulted in a 50% decrease of insulin biosynthesis under both conditions (Table 5) . In animal experiments L-asparaginase also induced hyperglycemia (12) associated with hyperinsulinemia when a single dose was given (1 3), but with decreased insulin levels after prolonged treatment (14) . Previous studies on isolated rabbit islets in short term incubation showed a reduced glucose induced insulin release only after exposure to very high doses of L-asparaginase, i.e. 1000-10000 U/mL (6) . Similar results were reported in rat islets incubated with 1000 U/mL (1 5).
Inasmuch as the L-asparaginase treatment most often is applied to children with acute lymphoblastic leukemia, the effect of the drug was primarily tested in islets from newborn rats. These islets appeared to be very sensitive to L-asparaginase since already 0.1 U/mL reduced the insulin release (Table I) , whereas higher concentrations resulted in disintegration of the islets. At least a partial reversibility was observed about 4 to 7 d after removal of L-asparaginase ( Fig. 1 ; Table 2 ), which is in agreement with both clinical observations (16) and animal experiments (6) . The high sensitivity of the newborn rat islets may be due to the lower asparagine synthetase activity in the pancreas compared with older animals (1 7) .
Adult rat islets were also affected, although at a higher dose of L-asparaginase ( Fig. 2 ; Table 3 ). Addition of hydrocortisone, however, potentiated the inhibitory effect in analogy with the combined treatment of L-asparaginase and prednisone in man and in rabbits (18) . Hydrocortisone was previously shown to influence glucose-induced insulin release and content in a bimodal manner on both mouse (1 9) and rat (20) islets in culture.
Because human islets are difficult to obtain due to scarcity of material, great variability of the pancreatic tissue and difficulties in the isolation and identification procedures (9) , it was only possible to test the effect of L-asparaginase in three cases which essentially confirmed the results found in rat islets ( Table 4) .
The concomitantly observed decrease in insulin release and insulin content of the islets cultured with L-asparaginase suggested that the drug affects insulin biosynthesis. This was also found to be the case (Table 5 ), but apparently the effect was not due to degradation of exogenous asparagine, because no effect on either release or insulin biosynthesis was seen by omission of this amino acid from the culture medium.
Although the glucagon content also was reduced in the adult rat islets exposed to 100 U/mL L-asparaginase, this was not seen in the newborn islets that were only exposed to 0.1 U/mL, indicating that the P-cells are more sensitive to the drug than are the a-cells. The lack of influence on the DNA content and the partial reversibility of the effect may suggest that the L-asparaginase does not kill the P-cells but rather inhibits insulin biosynthesis and release.
In conclusion, pancreatic P-cells appear to be particularly sensitive to L-asparaginase which may not be due to lack of exogenous asparagine. Whether a direct action on the cell membrane is involved remains to be studied. Thus the inhibitory effect of L-asparaginase on P-cell function as well as on lymphocyte proliferation is still not explained (2 1).
